Biocon/Fujifilm Enter Lantus Biosimilar Fray In Japan
This article was originally published in PharmAsia News
Executive Summary
Biocon and Fujifilm Pharma have received approval for their biosimilar insulin glargine from Japan's Ministry of Health, Labour and Welfare, marking what the Indian firm termed a "huge credibility milestone" and adding further pressure on innovator Sanofi's Lantus.